Israel-based EarlySense received FDA clearance for its bedside system and central display system with oximetry integration. EarlySense’s systems are based on a contact-free sensor placed under the mattress which can monitor respiration rate, heart rate and patient movement, and now the probably wired pulse oximeter (no pics yet) can provide additional critical data.
The company is promoting the additional capabilities of the system by noting that the Joint Commission’s recent Sentinel Event Alert recommended oxygenation and ventilation monitoring in post-op patients recovering on opioids. By offering a system that can do contact-free vitals monitoring, clinical staff has one less thing to hook up to the patient, making everyone involved free to do other things.
More about the company’s technology:
A sensing plate described in multiple pending patent applications with an integrated piezo-electric sensor is easily placed under the mattress so the patient remains comfortable and enjoys complete freedom of movement. There are no leads or cuffs.
Using groundbreaking signal processing techniques developed on a database of over 1,000,000 patient monitoring hours, EarlySense’s Embedded Algorithmic Engine converts the patients’ cardioballistic effect, respiratory motion pattern and large body movements into accurate vital signs and movement rate monitoring.
The patent pending sensing of motion enables effective filtration of artifacts for an extremely low overall alarm rate to prevent “alarm fatigue.”
The accurate results are transmitted and displayed automatically at the bedside, nurses’ station and on additional displays in centralized areas.
The data is also sent simultaneously to handheld devices to ensure intervention of all relevant caregivers throughout the unit.
Product page: EarlySense System…